Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.
Bioventus Inc. develops and commercializes medical device products for active healing, pain treatment, musculoskeletal care and surgical applications. The company organizes its portfolio around Pain Treatments, Restorative Therapies and Surgical Solutions, including products such as peripheral nerve stimulation devices, bone graft substitutes, ultrasonics, hyaluronic acid injections and ultrasound-based fracture healing therapies.
Recurring Bioventus news covers quarterly and annual results, financial guidance, revenue trends across its product areas and geographic markets, cash flow and margin performance, healthcare conference presentations, portfolio updates and regulatory developments affecting products such as Peripheral Nerve Stimulation offerings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Bioventus Inc. (BVS) announced the resignation of CEO Ken M. Reali as part of a leadership transition aimed at enhancing company performance. The board has appointed Anthony Bihl, a seasoned industry executive, as interim CEO. Bihl brings over 35 years of experience, including a previous tenure at Bioventus from 2013 to 2020. The board expressed gratitude for Reali's contributions while emphasizing the need to address company performance and unlock shareholder value. Bihl aims to stabilize operations and improve execution during this transitional phase, leveraging a differentiated product portfolio.